MAZE
Maze Therapeutics, Inc. Common Stock
NASDAQ: MAZE · HEALTHCARE · BIOTECHNOLOGY
$26.58
+3.50% today
Updated 2026-04-30
Market cap
$1.42B
P/E ratio
—
P/S ratio
501.65x
EPS (TTM)
$-3.05
Dividend yield
—
52W range
$8 – $54
Volume
0.9M
Maze Therapeutics, Inc. Common Stock (MAZE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | $149.96M | $71.50M | $240.54M |
| Cash & equivalents | — | — | — |
| Current assets | $106.15M | $34.11M | $201.67M |
| Total liabilities | $48.51M | $61.45M | $43.64M |
| Current liabilities | $20.78M | $16.32M | $20.67M |
| Long-term debt | — | $20.08M | — |
| Shareholder equity | — | — | — |
| Retained earnings | $-295.27M | $-395.69M | $-358.43M |
| Accounts receivable | — | — | — |
| Inventory | — | — | — |
| Goodwill | — | — | — |